NFATc1 as a therapeutic target in FLT3-ITD-positive AML
Stephan Metzelder(Philipps University of Marburg), Andreas Burchert(Philipps University of Marburg), Sabrina Inselmann(Philipps University of Marburg), Maria Solovey(Philipps University of Marburg), Miriam Rehberger(Philipps University of Marburg), Cornelia Brendel(Philipps University of Marburg), Elisabeth Heßmann(Universitätsmedizin Göttingen), Andreas Neubauer(RWTH Aachen University), Volker Ellenrieder, Christian Michel(Philipps University of Marburg), Stefan Gattenlöhner(Justus-Liebig-Universität Gießen), Kristina Sohlbach(Philipps University of Marburg), Thorsten Stiewe(Philipps University of Marburg), Joël P. Charles, Ying Wang(Third Affiliated Hospital of Guangzhou Medical University), Malte von Bonin(Städtisches Klinikum Dresden), Andre ten Haaf(Universitätsklinikum Gießen und Marburg), Martin Bornhäuser(Technische Universität Dresden)
Cited by 52
Related Papers
Diverse Applications of Nanomedicine
|ACS Nano|2017|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573